首页> 美国卫生研究院文献>The Journal of Clinical Investigation >Studies in porphyria: functional evidence for a partial deficiency of ferrochelatase activity in mitogen-stimulated lymphocytes from patients with erythropoietic protoporphyria.
【2h】

Studies in porphyria: functional evidence for a partial deficiency of ferrochelatase activity in mitogen-stimulated lymphocytes from patients with erythropoietic protoporphyria.

机译:卟啉症的研究:功能性证据表明促红细胞性原卟啉症患者的有丝分裂原刺激的淋巴细胞中的铁螯合酶活性部分不足。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In this paper we show that the ferrochelatase defect in erythropoietic protoporphyria (EPP) can readily be identified in mitogen-stimulated lymphocytes since such cells from patients with EPP accumulate approximately twice as much protoporphyrin IX as cells from normal subjects when incubated with a porphyrin precursor, gamma-aminolevulinic acid (ALA). Treatment of cultures with ALA and with the iron chelator, CaMgEDTA significantly increased the level of protoporphyrin IX in mitogen-stimulated lymphocytes from normal subjects, while the same treatment failed to produce an increase in protoporphyrin IX in cell preparations from EPP patients. In contrast to the results with the chelator treatment, supplementation of the cultures with iron and ALA reduced the level of protoporphyrin IX in normal cells, but not in EPP cells. These findings are compatible with a partial deficiency of ferrochelatase in EPP lymphocytes. The gene defects of acute intermittent porphyria and hereditary coproporphyria have previously been identified using lymphocyte preparations from the gene carriers of these diseases. The present study demonstrates that EPP represents another form of human porphyria in which the gene defect of the disease can now be identified in lymphocyte preparations.
机译:本文显示,促红细胞原卟啉症(EPP)中的铁螯合酶缺陷很容易在促细胞分裂剂刺激的淋巴细胞中发现,因为当与卟啉前体孵育时,来自EPP患者的此类细胞积聚的原卟啉IX约为正常受试者细胞的两倍, γ-氨基乙酰丙酸(ALA)。 CaMgEDTA用ALA和铁螯合剂处理培养物可显着增加正常受试者的促有丝分裂原刺激的淋巴细胞中原卟啉IX的水平,而相同的处理未能使EPP患者的细胞制剂中原卟啉IX的增加。与螯合剂处理的结果相反,用铁和ALA补充培养物可降低正常细胞中原卟啉IX的水平,但不能降低EPP细胞中的原卟啉IX的水平。这些发现与EPP淋巴细胞中的铁螯合酶的部分缺乏是相容的。急性间歇性卟啉症和遗传性卟啉症的基因缺陷先前已使用来自这些疾病的基因载体的淋巴细胞制剂进行了鉴定。本研究表明,EPP代表人类卟啉症的另一种形式,其中该疾病的基因缺陷现在可以在淋巴细胞制品中鉴定出来。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号